Search - tctmd.com

Displaying 1 - 20 of 74

Sort: Relevancy | Date

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

News Daily News

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Caitlin E. Cox

October 22, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2025

Caitlin E. Cox

July 31, 2025

News Daily News

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

L.A. McKeown

July 24, 2025

News Daily News

Weight-Loss Medications Should Be Part of Cardiology’s Arsenal: ACC

Michael O'Riordan

June 25, 2025

News Opinion CV Team Dispatch

January 2025 Dispatch for the CV Team

L.A. McKeown

January 24, 2025

News Daily News

‘Disproportionate’ Suicide/Self-Harm Signal With Semaglutide: WHO Database

Michael O'Riordan

August 21, 2024

News Daily News

No Uptick in Suicidal Thinking With GLP-1 Drugs: Medicare Data

Yael L. Maxwell

July 15, 2024

News Daily News

EMA: No Evidence of Link Between GLP-1 Receptor Agonists and Suicidal Thoughts

Todd Neale

April 12, 2024

News Daily News

Injectable Semaglutide Shortage Forces Physicians to Pivot

Todd Neale

February 05, 2024

News Daily News

FDA: No Signs of Link Between GLP-1s and Suicidal Thoughts, Actions

Todd Neale

January 12, 2024

News Daily News

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

Michael O'Riordan

December 08, 2023

News Daily News

GLP-1 Meds Linked to 265 Reports to FDA of Suicidal Ideation: Reuters

Shelley Wood

September 28, 2023

News Daily News

EMA Investigating Suicidal Thinking With GLP-1 Drugs for Weight Loss

Michael O'Riordan

July 12, 2023

News Daily News

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

Shelley Wood

May 30, 2023

News Features

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

L.A. McKeown

May 12, 2023

News Daily News

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Michael O'Riordan

January 05, 2023

News Daily News

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

Michael O'Riordan

December 30, 2022

News Conference News AHA 2022

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

Michael O'Riordan

November 06, 2022

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

Advertisement

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

TCTMD’s Top 10 Most Popular Stories for July 2025

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

Weight-Loss Medications Should Be Part of Cardiology’s Arsenal: ACC

January 2025 Dispatch for the CV Team

‘Disproportionate’ Suicide/Self-Harm Signal With Semaglutide: WHO Database

No Uptick in Suicidal Thinking With GLP-1 Drugs: Medicare Data

EMA: No Evidence of Link Between GLP-1 Receptor Agonists and Suicidal Thoughts

Injectable Semaglutide Shortage Forces Physicians to Pivot

FDA: No Signs of Link Between GLP-1s and Suicidal Thoughts, Actions

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

GLP-1 Meds Linked to 265 Reports to FDA of Suicidal Ideation: Reuters

EMA Investigating Suicidal Thinking With GLP-1 Drugs for Weight Loss

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content